Clasp Therapeutics Publishes Preclinical Data on CLSP-1025, the First Clinical-Stage T-Cell Engager Targeting an Intracellular Driver Mutation, in Clinical Cancer Research

GO BACK TO PRESS RELEASES & MEDIA Press Release July 24, 2026 Clasp Therapeutics Publishes Preclinical Data on CLSP-1025, the First Clinical-Stage T-Cell Engager Targeting an Intracellular Driver Mutation, in Clinical Cancer Research Peer-reviewed publication details the preclinical characterization of CLSP-1025, a first-in-class T-cell engager (TCE) designed to selectively target cancer cells expressing the p53 R175H neoantigen, the most common p53 hotspot mutation Data demonstrate potent, mutation-specific anti-tumor activity with extensive characterization of selectivity and safety Findings